|
|
Article: Taro Pharmaceuticals and IVAX's Subsidiary, Zenith Goldline Pharmaceuticals, to Co-Market Warfarin Tablets.
- Article from:
- Business Wire
- Article date:
- August 18, 1999
CopyrightCOPYRIGHT 1999 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
HAWTHORNE, N.Y.--(BUSINESS WIRE)--Aug. 18, 1999--
Alliance Furthers Taro's Strategic Goal to Build Strong
U.S. Market Presence in Solid Dosage Form Products
Taro Pharmaceutical Industries Ltd. (NASDAQ/NMS:TAROF) today announced that it has entered into an agreement with Zenith Goldline Pharmaceuticals, Inc. for the co-marketing in the U.S. of all nine strengths of Taro's recently FDA approved Warfarin Sodium Tablets USP.
The agreement also provides for the co-marketing and/or supply in the U.S. by both parties of certain other products already marketed or under development.
Zenith Goldline, a subsidiary of IVAX Corporation, is ...